Overview of HCV Life Cycle With a Special Focus on Current and Possible Future Antiviral Targets

Viruses. 2019 Jan 6;11(1):30. doi: 10.3390/v11010030.


Hepatitis C infection is the leading cause of liver diseases worldwide and a major health concern that affects an estimated 3% of the global population. Novel therapies available since 2014 and 2017 are very efficient and the WHO considers HCV eradication possible by the year 2030. These treatments are based on the so-called direct acting antivirals (DAAs) that have been developed through research efforts by academia and industry since the 1990s. After a brief overview of the HCV life cycle, we describe here the functions of the different targets of current DAAs, the mode of action of these DAAs and potential future inhibitors.

Keywords: DAA; HCV; antiviral targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology*
  • Hepacivirus / drug effects
  • Hepacivirus / physiology*
  • Hepatitis C / drug therapy*
  • Humans
  • Molecular Targeted Therapy
  • Protease Inhibitors / pharmacology


  • Antiviral Agents
  • Protease Inhibitors